PharmaMar announces that it has received payment of $100 million from Jazz Pharmaceuticals for the approval of Zepzelca™ (lurbinectedin) in the U.S.

- **PharmaMar could receive up to an additional US $150 million when full approval is achieved.**
- **On June 15th, 2020 lurbinectedin was approved by the FDA for the treatment of adult patients with metastatic Small Cell Lung Cancer (SCLC) with disease progression.**
- **Jazz Pharmaceuticals to launch lurbinectedin in the U.S. in July.**

Madrid, June 29th, 2020.- PharmaMar (MSE:PHM) has today announced that it has received payment of $100 million from Jazz Pharmaceuticals, corresponding to the first part of the regulatory milestones, for the approval of lurbinectedin in the U.S. for the treatment of patients with metastatic SCLC.

PharmaMar could receive up to an additional US $150 million once full approval is achieved.

As reported on December 19th, 2019, with the signing of the agreement between the two companies, PharmaMar will receive royalties, based on lurbinectedin's net sales, ranging from a percentage in the high teens, up to a maximum of 30 percent. In addition, PharmaMar may receive up to an additional US $550 million for commercial objectives.

On June 15th, 2020, PharmaMar and Jazz Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) had approved Zepzelca™ (lurbinectedin) for the treatment of adult patients with metastatic SCLC with disease progression, after platinum-based chemotherapy. Lurbinectedin was approved under "Accelerated Approval" based on Overall Response Rate (ORR) and Duration of Response (DoR).

The FDA approval of this drug is based on monotherapy clinical data from an open-label, multi-center, single-arm study in 105 adult platinum-sensitive and platinum-resistant patients with relapsed SCLC[1]. The data, which appeared in the May 2020 issue of *The Lancet Oncology*, showed that in relapsed SCLC, lurbinectedin demonstrated an ORR of 35 percent and a median DoR of 5.3 months as measured by investigator assessment (30 percent and 5.1 months respectively, as measured by an independent review committee (IRC).

This approval will allow Jazz to make lurbinectedin (Zepzelca™) commercially available in the U.S. in July.

Legal Statement

This press release does not constitute an offer to sell or the solicitation of an offer to buy securities, and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of that jurisdiction.

About PharmaMar

Headquartered in Madrid, PharmaMar is a biopharmaceutical company, focused on oncology and committed to research and development which takes its inspiration from the sea to discover molecules with antitumor activity. It is a company that seeks innovative products to provide healthcare professionals with new tools to treat cancer. Its commitment to patients and to research has made it one of the world leaders in the discovery of antitumor drugs of marine origin.

PharmaMar has a pipeline of drug candidates and a robust R&D oncology program. It develops and commercializes Yondelis® in Europe and has other clinical-stage programs under development for several types of solid cancers: Zepzelca™ (lurbinectedin, PM1183), PM184 and PM14. With subsidiaries in Germany, Italy, France, Switzerland, Belgium, Austria and the United States. PharmaMar wholly owns other companies: GENOMICA, a molecular diagnostics company; Sylentis, dedicated to researching therapeutic applications of gene silencing (RNAi). To learn more about PharmaMar, please visit us at www.pharmamar.com.

About lurbinectedin

Lurbinectedin (Zepzelca™), also known as PM1183, is an analog of the marine compound ET-736 isolated from the sea squirt *Ecteinacidia turbinata* in which a hydrogen atom has been replaced by a methoxy group. It is a selective inhibitor of the oncogenic transcription programs on which many tumors are particularly dependent. Together with its effect on cancer cells, lurbinectedin inhibits oncogenic transcription in tumor-associated macrophages, downregulating the production of cytokines that are essential for the growth of the tumor. Transcriptional addiction is an acknowledged target in those diseases, many of them lacking other actionable targets.

Media Contact:

Alfonso Ortín – Communications Director aortin@pharmamar.com Mobile: +34 609493127
Miguel Martínez-Cava – Communication Manager mmartinez-cava@pharmamar.com Mobile: +34 606597464
Phone: +34 918466000

Capital Markets & Investor Relations:

José Luis Moreno– Capital Markets & Investor Relations Director
María Marín de la Plaza – Capital Markets & Investor Relations
investorrelations@pharmamar.com
Phone: +34 914444500

Or please visit our website at www.pharmamar.com

[1] Trigo J, Subbiah V, Besse B, et al. Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial. Lancet Oncol. 2020 May;21(5):645-654.